Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Pfizer | INDUSTRY |
Not provided
Not provided
Not provided
This study is to learn about flu and COVID vaccines, either alone or when mixed together. Healthy people aged 18 or older can join. Participants will get one shot in each arm, either a flu or COVID vaccine, alone or mixed. The study lasts about 6 months, and participants need to visit the research site at least 3 times.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Arm A | Experimental | COVID-19 Vaccine (Dose 1) and Placebo |
|
| Arm B | Experimental | COVID-19 Vaccine (Dose 2) and Placebo |
|
| Arm C | Active Comparator | COVID-19 Vaccine (Dose 3) and Placebo |
|
| Arm D | Experimental | Investigational Influenza Vaccine (Dose 1) and Placebo |
|
| Arm E | Active Comparator | Licensed Influenza Vaccine 1 and COVID-19 Vaccine (Dose 3) |
|
| Arm EE | Active Comparator |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Investigational Influenza Vaccine | Biological | Investigational Influenza Vaccine |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of participants reporting prompted local reactions within 7 days following investigational product administration | Describe prompted local reactions following investigational product administration | Day 7 |
| Percentage of participants reporting prompted systemic events within 7 days following investigational product administration | Describe prompted systemic events following investigational product administration | Day 7 |
| Percentage of participants reporting adverse events (AEs) through 4 weeks following investigational product administration | Describe AEs occurring through 4 weeks following administration of investigational product | 4 weeks after vaccination |
| Percentage of participants reporting serious adverse events (SAEs) through 6 months following investigational product administration | Describe SAEs through 6 months following administration of investigational product | 6 months after vaccination |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Please refer to the study contact for further eligibility details.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Orange County Research Center | Lake Forest | California | 92630 | United States | ||
| Artemis Institute for Clinical Research |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Licensed Influenza Vaccine 2 and COVID-19 Vaccine (Dose 3)
|
| Arm F | Experimental | Investigational Influenza Vaccine (Dose 2) and Placebo |
|
| Arm G | Experimental | Influenza and COVID Combination Vaccine (Combination 1) and Placebo |
|
| Arm H | Experimental | Influenza and COVID Combination Vaccine (Combination 2) and Placebo |
|
| Arm I | Experimental | Influenza and COVID Combination Vaccine (Combination 3) and Placebo |
|
| Arm J | Experimental | Investigational Influenza Vaccine (Dose 3) and Placebo |
|
| Arm K | Experimental | Influenza and COVID Combination Vaccine (Combination 4) and Placebo |
|
| Arm L | Experimental | Influenza and COVID Combination Vaccine (Combination 5) and Placebo |
|
| Arm M | Experimental | Influenza and COVID Combination Vaccine (Combination 6) and Placebo |
|
| Arm N | Experimental | Influenza and COVID Combination Vaccine (Combination 7) and Placebo |
|
| COVID-19 Vaccine | Biological | Pfizer-BioNTech COVID-19 Vaccine |
|
| Influenza and COVID Combination Vaccine | Combination Product | Combined investigational influenza and Pfizer-BioNTech COVID-19 Vaccine |
|
| Licensed Influenza Vaccine 1 | Biological | Licensed Influenza Vaccine 1 |
|
| Licensed Influenza Vaccine 2 | Biological | Licensed Influenza Vaccine 2 |
|
| Placebo | Other | Saline |
|
| San Diego |
| California |
| 92103 |
| United States |
| Diablo Clinical Research, Inc. | Walnut Creek | California | 94598 | United States |
| Clinical Research Consulting | Milford | Connecticut | 06460 | United States |
| Indago Research & Health Center, Inc | Hialeah | Florida | 33012 | United States |
| Miami Dade Medical Research Institute, LLC | Miami | Florida | 33176 | United States |
| Palm Springs Community Health Center | Miami Lakes | Florida | 33014 | United States |
| Headlands Research Orlando | Orlando | Florida | 32819 | United States |
| Clinical Research Atlanta | Stockbridge | Georgia | 30281 | United States |
| East-West Medical Research Institute | Honolulu | Hawaii | 96814 | United States |
| Clinical Research Professionals | Chesterfield | Missouri | 63005 | United States |
| Bio-Kinetic Clinical Applications, LLC dba QPS-MO | Springfield | Missouri | 65802 | United States |
| Bio-Kinetic Clinical Applications, LLC dba QPS-MO-Screening and Recruitment Center | Springfield | Missouri | 65807 | United States |
| Velocity Clinical Research, Omaha | Omaha | Nebraska | 68134 | United States |
| Las Vegas Clinical Trials | Las Vegas | Nevada | 89030 | United States |
| ActivMed Practices & Research, LLC. | Portsmouth | New Hampshire | 03801 | United States |
| DM Clinical Research- Cyfair | Houston | Texas | 77065 | United States |
| SMS Clinical Research | Mesquite | Texas | 75149 | United States |
| Dynamed Clinical Research, LP d/b/a DM Clinical Research | Tomball | Texas | 77375 | United States |
| J. Lewis Research, Inc. / Foothill Family Clinic | Salt Lake City | Utah | 84109 | United States |
| J. Lewis Research, Inc. / Foothill Family Clinic South | Salt Lake City | Utah | 84121 | United States |
| Charlottesville Medical Research | Charlottesville | Virginia | 22911 | United States |
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Jun 29, 2026 |
| ID | Term |
|---|---|
| D007251 | Influenza, Human |
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D009976 | Orthomyxoviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D012140 | Respiratory Tract Diseases |
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D008171 | Lung Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000086663 | COVID-19 Vaccines |
| D007252 | Influenza Vaccines |
| ID | Term |
|---|---|
| D014765 | Viral Vaccines |
| D014612 | Vaccines |
| D001688 | Biological Products |
| D045424 | Complex Mixtures |
Not provided
Not provided